Novavax Bounces Back From Seven-Day Slide, Eyes 2028 Profitability

viernes, 21 de noviembre de 2025, 1:06 pm ET1 min de lectura
NVAX--

Novavax (NVAX) rose 4.98% to $6.53, snapping a seven-session losing streak. The company now expects to reach profitability in 2028, with the timing tied to its vaccine sales. Novavax's stock had fallen on November 18 and 19, with drops of 3.38% and 3.50%, respectively.

Novavax Bounces Back From Seven-Day Slide, Eyes 2028 Profitability

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios